SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

SAN

97.74

-0.91%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

ARGX

544.2

-1.13%↓

Strona główna・Stock List・UCB SA

UCB SA

Closed

Sector Healthcare

178.7 -0.97

Buy Sell

Overview

Share price change

24h

Current

Min

177.55

Max

181.3

Key metrics
By Trading Economics
Income	104M
Sales	127M 2.8B
P/E Sector Avg	26.67 104.138
EPS	2.09
Profit margin	3.728

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+19.23 upside

Market Stats
By TradingEconomics
Market Cap	598M 34B
Previous open	179.67
Previous close	178.7

News Sentiment

By Acuity

64%

36%

328 / 390 Ranking in Healthcare

UCB SA Chart

Past performance is not a reliable indicator of future results.

Related News

5 gru 2023, 16:47 UTC

Market Talk

European Pharmas With New Drugs Hold Most Promise in 2024 -- Market Talk

Peer Comparison

Price change

UCB SA Forecast

Price Target

By TipRanks

19.23% upside

12 Months Forecast

Average 94.86 EUR 19.23%

High 125 EUR

Low 74 EUR

Based on 7 Wall Street analysts offering 12 month price targets forUCB SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to UCB SA - Dist in the past 3 months.

Sentiment

By Acuity

328 / 390 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.